Form 4: Apellis Pharmaceuticals Director Sinclair Dunlop Sells Shares

Director Sinclair Dunlop of Apellis Pharmaceuticals sold 18,681 shares of common stock at an average price of $57.179 on March 19, 2024.

Summary

• On March 19, 2024, Sinclair A. Dunlop, a director of Apellis Pharmaceuticals, sold 18,681 shares of common stock.
• The sale was executed at a weighted average price of $57.179 per share, with individual trades ranging from $57.000 to $57.420.
• Following the transaction, Dunlop directly owns 132,018 shares and indirectly owns 173,998 shares through Epidarex Capital I, LP and 31,855 shares through MASA.
• Dunlop disclaims beneficial ownership of the shares held by Epidarex and MASA, except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: Neutral. This is a standard disclosure of stock sales by a company director. It doesn't inherently indicate positive or negative sentiment about the company's future prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity, which is common for directors and officers of publicly traded companies. It provides transparency to investors regarding the buying and selling of company stock by its leadership.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, potentially leading to a slight decrease in stock price, although this is not guaranteed.

Key Dates